Genetic modifiers of Huntingtons disease: Beyond CAG

Future Neurology

Volumn 7, Issue 1, 2012, Pages 93-109

  Arning, Larissa ^a   Epplen, Jörg T ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

ADORA2A; age at onset; GRIN2A; GRIN2B; HAP1; Huntingtons disease; modifier genes; PPARGC1A; TCERG1; UCHL

Indexed keywords

ADENOSINE A2A RECEPTOR; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; UBIQUITIN CARBOXYTERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADENOSINE A2A RECEPTOR GENE; APOE GENE; APOPTOSIS; ATG7 GENE; AUTOPHAGY; AUTOSOMAL DOMINANT INHERITANCE; BDNF GENE; CAG REPEAT; CELLULAR STRESS RESPONSE; DFFB GENE; DNA REPAIR; GENE; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENETIC RISK; GRIK2 GENE; GRIN2A GENE; GRIN2B GENE; HAP1 GENE; HUMAN; HUNTINGTIN GENE; HUNTINGTON CHOREA; MAP2K6 GENE; MAP3K5 GENE; NEUROPATHOLOGY; NONHUMAN; NRF1 GENE; OGG1 GENE; PPARGC1A GENE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TCERG1 GENE; TFAM GENE; TUMOR SUPPRESSOR GENE; UCHL1 GENE;

EID: 83655191480     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.11.65     Document Type: Review

References (92)

1. Frazer KA, Murray SS, Schork NJ et al. Human genetic variation and its contribution to complex traits. Nat. Rev. Genet. 10(4), 241-251 (2009).
2. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72(6), 971-983 (1993).
3. McNeil SM, Novelletto A, Srinidhi J et al. Reduced penetrance of the Huntington's disease mutation. Hum. Mol. Genet. 6(5), 775-779 (1997). (Pubitemid 27199071)
4. Warby SC, Visscher H, Collins JA et al. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur. J. Hum. Genet. 19(5), 561-566 (2011).
5. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov. Disord. 11(2), 136-142 (1996).
6. Duyao M, Ambrose C, Myers R et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4(4), 387-392 (1993). (Pubitemid 23231488)
7. Snell RG, MacMillan JC, Cheadle JP et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 4(4), 393-397 (1993). (Pubitemid 23231489)
8. Gusella JF, MacDonald ME. Huntington's disease. Semin. Cell Biol. 6(1), 21-28 (1995).
9. Andrew SE, Goldberg YP, Kremer B et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 4(4), 398-403 (1993). (Pubitemid 23231490)
10. Li JL, Hayden MR, Almqvist EW et al. A genome scan for modifiers of age at onset in Huntington disease: the HD MAPS study. Am. J. Hum. Genet. 73(3), 682-687 (2003). (Pubitemid 37076283)
11. Li JL, Hayden MR, Warby SC et al. Genome-wide significance for a modifier of age at neurological onset in Huntingtons disease at 6q23-24: the HD MAPS study. BMC Med. Genet. 7, 71 (2006).
12. Gayán J, Brocklebank D, Andresen JM et al. Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds. Genet. Epidemiol. 32(5), 445-453 (2008).
13. Farrer LA, Cupples LA, Wiater P et al. The normal Huntington disease (HD) allele, or a closely linked gene, influences age at onset of HD. Am. J. Hum. Genet. 53(1), 125-130 (1993). (Pubitemid 23313743)
14. Kehoe P, Krawczak M, Harper PS et al. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J. Med. Genet. 36(2), 108-111 (1999). (Pubitemid 29101384)
15. Djousse L, Knowlton B, Hayden M et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am. J. Med. Genet. 119A(3), 279-182 (2003).
16. Aziz NA, Jurgens CK, Landwehrmeyer GB et al. Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Neurology 73(16), 1280-1285 (2009).
17. Novelletto A, Persichetti F, Sabbadini G et al. Polymorphism analysis of the huntingtin gene in Italian families affected with Huntington disease. Hum. Mol. Genet. 3(7), 1129-1132 (1994). (Pubitemid 24211958)
18. Rubinsztein DC, Leggo J, Chiano M et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc. Natl Acad. Sci. USA 94(8), 3872-3876 (1997). (Pubitemid 27180465)
19. Andresen JM, Gayán J, Djoussé L et al. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Ann. Hum. Genet. 71(Pt 3), 295-301 (2007). (Pubitemid 46585671)
20. Arning L, Haghikia A, Taherzadeh-Fard E et al. Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J. Mol. Med. 88(4), 431-436 (2010).
21. Klempír J, Zidovská J, Stochl J et al. The number of CAG repeats within the normal allele does not influence the age of onset in Huntington's disease. Mov. Disord. 26(1), 125-129 (2011)
22. Rubinsztein DC, Barton DE, Davison BC et al. Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington disease and CAG repeat number. Hum. Mol. Genet. 2(10), 1713-1715 (1993). (Pubitemid 23358694)
23. Ambrose CM, Duyao MP, Barnes G et al. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Som. Cell Mol. Genet. 20(1), 27-38 (1994). (Pubitemid 24161062)
24. Lucotte G, Gérard N, Roubertoux P et al. Relationships of the 2642 deletion polymorphism (delta 2642) in the huntingtin gene with the CAG repeat expansion length and age at onset of the disease. Genet. Couns. 7(4), 297-302 (1996). (Pubitemid 26421640)
25. Vuillaume I, Vermersch P, Destée A et al. Genetic polymorphisms adjacent to the CAG repeat influence clinical features at onset in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 64(6), 758-762 (1998). (Pubitemid 28274410)
26. Chattopadhyay B, Ghosh S, Gangopadhyay PK et al. Modulation of age at onset in Huntington's disease and spinocerebellar ataxia type 2 patients originated from eastern India. Neurosci. Lett. 345(2), 93-96 (2003). (Pubitemid 36734870)
27. Wang CK, Wu YR, Hwu WL et al. DNA haplotype analysis of CAG repeat in Taiwanese Huntington's disease patients. Eur. Neurol. 52(2), 96-100 (2004). (Pubitemid 39274291)
28. Djoussé L, Knowlton B, Hayden MR et al. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics 5(2), 109-114 (2004). (Pubitemid 38828670)
29. Ribeiro FM, Pires RG, Ferguson SS. Huntington's disease and group I metabotropic glutamate receptors. Mol. Neurobiol. 43(1), 1-11 (2011).
30. Seredenina T, Luthi-Carter R. What have we learned from gene expression profiles in Huntington's disease? Neurobiol. Dis. 45(1) 83-98 (2012).
31. MacDonald ME, Vonsattel JP, Shrinidhi J et al. Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology 53(6), 1330-1332 (1999). (Pubitemid 29480096)
32. Naze P, Vuillaume I, Destee A et al. Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. Neurosci. Lett. 328(1), 1-4 (2002). (Pubitemid 34786029)
33. Cannella M, Gellera C, Maglione V et al. The gender effect in juvenile Huntington disease patients of Italian origin. Am. J. Med. Genet. B Neuropsychiatr. Genet. 125B(1), 92-98 (2004). (Pubitemid 38141411)
34. Arning L, Kraus PH, Valentin S et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics 6, 25-28 (2005). (Pubitemid 40394827)
35. Metzger S, Bauer P, Tomiuk J et al. Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease. Hum. Genet. 120(2), 285-292 (2006). (Pubitemid 44204017)
36. Andresen JM, Gayán J, Cherny SS et al. Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J. Med. Genet. 44(1), 44-50 (2007).
37. Zeng W, Gillis T, Hakky M et al. Genetic analysis of the GRIK2 modifier effect in Huntington's disease. BMC Neurosci. 7, 62 (2006).
38. Milnerwood AJ, Raymond LA. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 33(11), 513-523 (2010).
39. Fan MM, Raymond LA. N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 81(5-6), 272-293 (2007). (Pubitemid 46528641)
40. Li L, Fan M, Icton CD et al. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol. Aging 24(8), 1113-1121 (2003). (Pubitemid 37487889)
41. Arning L, Saft C, Wieczorek S et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum. Genet. 122(2), 175-182 (2007). (Pubitemid 47241782)
42. Saft C, Epplen JT, Wieczorek S et al. NMDA receptor gene variations as modifiers in Huntington disease: a replication study. PLoS Curr. 3, RRN1247 (2011).
43. Popoli P, Blum D, Martire A et al. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog. Neurobiol. 81(5-6), 331-348 (2007). (Pubitemid 46528642)
44. Dhaenens CM, Burnouf S, Simonin C et al. A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiol. Dis. 35(3), 474-476 (2009).
45. Taherzadeh-Fard E, Saft C, Wieczorek S et al. Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics 11(4), 435-439 (2010).
46. DiFiglia M, Sapp E, Chase KO et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277(5334), 1990-1993 (1997). (Pubitemid 27449140)
47. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 20(3), 146-154 (2004).
48. Kaltenbach LS, Romero E, Becklin RR et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 3(5), E82 (2007).
49. Holbert S, Denghien I, Kiechle T et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc. Natl Acad. Sci. USA 98(4), 1811-1816 (2001). (Pubitemid 32165580)
50. Li XJ, Li SH, Sharp AH et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378(6555), 398-402 (1995).
51. Wu LL, Zhou XF. Huntingtin associated protein 1 and its functions. Cell Adh. Migr. 3(1), 71-76 (2009).
52. Metzger S, Rong J, Nguyen HP et al. Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease. Hum. Mol. Genet. 17(8), 1137-1146 (2008). (Pubitemid 351494185)
53. Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J. Clin. Invest. 121(2), 493-499 (2011).
54. Lin J, Wu PH, Tarr PT et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119(1), 121-135 (2004). (Pubitemid 39349325)
55. Leone TC, Lehman JJ, Finck BN et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PloS Biol. 3(4), E101 (2005).
56. Cui L, Jeong H, Borovecki F et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127(1), 59-69 (2006). (Pubitemid 44466642)
57. Weydt P, Pineda VV, Torrence AE et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 4(5), 349-362 (2006). (Pubitemid 44645069)
58. Weydt P, Soyal SM, Gellera C et al. The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol. Neurodegener. 4, 3 (2009).
59. Taherzadeh-Fard E, Saft C, Andrich J et al. PGC-1alpha as modifier of onset age in Huntington disease. Mol. Neurodegener. 4, 10 (2009).
60. Che HV, Metzger S, Portal E et al. Localization of sequence variations in PGC-1alpha influence their modifying effect in Huntington disease. Mol. Neurodegener. 6(1), 1 (2011).
61. Wallace DC, Brown MD, Lott MT. Mitochondrial DNA variation in human evolution and disease. Gene 238(1), 211-230 (1999). (Pubitemid 29436110)
62. Mancuso M, Kiferle L, Petrozzi L et al. Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype. Neurosci. Lett. 444(1), 83-86 (2008).
63. Taherzadeh-Fard E, Saft C, Akkad DA et al. PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease. Mol. Neurodegener. 6(1), 32 (2011).
64. Hickey MA, Chesselet MF. Apoptosis in Huntington's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(2), 255-265 (2003).
65. Arning L, Monté D, Hansen W et al. ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease. J. Mol. Med. (Berl.) 86(4), 485-490 (2008).
66. Widlak P, Garrard WT. Roles of the major apoptotic nuclease-DNA fragmentation factor-in biology and disease. Cell Mol. Life Sci. 66(2), 263-274 (2009).
67. Chattopadhyay B, Baksi K, Mukhopadhyay S et al. Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes. Neurosci. Lett. 374(2), 81-86 (2005). (Pubitemid 40092201)
68. Arning L, Kraus PH, Saft C et al. Age at onset of Huntington disease is not modulated by the R72P variation in TP53 and the R196K variation in the gene coding for the human caspase activated DNase (hCAD). BMC Med. Genet. 6, 35 (2005).
69. Marin MC, Jost CA, Brooks LA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25(1), 47-54 (2000). (Pubitemid 30257035)
70. Ross CA, Pickart CM. The ubiquitin- proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 14(12), 703-711 (2004). (Pubitemid 39572556)
71. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimers disease. Proc. Natl Acad. Sci. USA 103(15), 5644-5645 (2006).
72. Panas M, Avramopoulos D, Karadima G et al. Apolipoprotein E and presenilin-1 genotypes in Huntington's disease. J. Neurol. 246(7), 574-577 (1999). (Pubitemid 29376283)
73. Saft C, Andrich JE, Brune N et al. Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 75(12), 1692-1696 (2004). (Pubitemid 39611467)
74. Leroy E, Boyer R, Auburger G et al. The ubiquitin pathway in Parkinson's disease. Nature 395(6701), 451-452 (1998).
75. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem. Int. 51(2-4), 105-111 (2007). (Pubitemid 47179898)
76. Metzger S, Bauer P, Tomiuk J et al. The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease. Neurogenetics 7(1), 27-30 (2006). (Pubitemid 43327681)
77. Xu EH, Tang Y, Li D, Jia JP. Polymorphism of HD and UCHL-1 genes in Huntington's disease. J. Clin. Neurosci. 16(11), 1473-1477 (2009).
78. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5(6), 311-322 (2009).
79. Egan MF, Kojima M, Callicott JH et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2), 257-269 (2003). (Pubitemid 36144114)
80. Chen ZY, Patel PD, Sant G et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J. Neurosci. 24(18), 4401-4411 (2004). (Pubitemid 38608151)
81. del Toro D, Canals JM, Ginés S et al. Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. J. Neurosci. 26(49), 12748-12757 (2006). (Pubitemid 44904570)
82. Alberch J, Lopez M, Badenas C et al. Association between BDNF Val66Met polymorphism and age at onset in Huntington disease. Neurology 65(6), 964-965 (2005). (Pubitemid 41362158)
83. Di Maria E, Marasco A, Tartari M et al. No evidence of association between BDNF gene variants and age-at-onset of Huntington's disease. Neurobiol. Dis. 24(2), 274-279 (2006). (Pubitemid 44604334)
84. Kishikawa S, Li JL, Gillis T et al. Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease. Neurobiol. Dis. 24(2), 280-285 (2006). (Pubitemid 44572754)
85. Mai M, Akkad AD, Wieczorek S et al. No association between polymorphisms in the BDNF gene and age at onset in Huntington disease. BMC Med. Genet. 7, 79 (2006).
86. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 81(5-6), 294-330 (2007). (Pubitemid 46528643)
87. Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 13(7), 805-811 (2010).
88. Yamamoto A, Cremona ML, Rothman JE. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J. Cell Biol. 172(5), 719-731 (2006).
89. Metzger S, Saukko M, Van Che H et al. Age at onset in Huntington's disease is modified by the autophagy pathway: implication of the V471A polymorphism in Atg7. Hum. Genet. 128(4), 453-459 (2010).
90. Kovtun IV, Liu Y, Bjoras M et al. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature 447(7143), 447-452 (2007). (Pubitemid 46816735)
91. Bravard A, Vacher M, Moritz E et al. Oxidation status of human OGG1-S326C polymorphic variant determines cellular DNA repair capacity. Cancer Res. 69(8), 3642-3649 (2009).
92. Coppedé F, Migheli F, Ceravolo R et al. The hOGG1 Ser326Cys polymorphism and Huntington's disease. Toxicology 278(2), 199-203 (2010)